Following
its introduction as an alternative to perfluorooctanoic
acid, hexafluoropropylene oxide dimer acid (HFPO-DA) has been extensively
detected in various environmental matrices. Despite this prevalence,
limited information is available regarding its hepatotoxicity biomarkers.
In this study, toxicokinetic simulations indicated that under repeated
treatment, HFPO-DA in mice serum reached a steady state by the 4th
day. To assess its subacute hepatic effects and identify potential
biomarkers, mice were administered HFPO-DA orally at doses of 0, 0.1,
0.5, 2.5, 12.5, or 62.5 mg/kg/d for 7 d. Results revealed that the
lowest observed adverse effect levels were 0.5 mg/kg/d for hepatomegaly
and 2.5 mg/kg/d for hepatic injury. Serum metabolomics analysis identified
34, 58, and 118 differential metabolites in the 0.1, 0.5, and 2.5
mg/kg/d groups, respectively, compared to the control group. Based
on weighted gene coexpression network analysis, eight potential hepatotoxicity-related
metabolites were identified; among them, kynurenic acid (KA) in mouse
serum exhibited the highest correlation with liver injury. Furthermore,
liver-targeted metabolomics analysis demonstrated that HFPO-DA exposure
induced metabolic migration of the kynurenine pathway from KA to nicotinamide
adenine dinucleotide, resulting in the activation of endoplasmic reticulum
stress and the nuclear factor kappa-B signaling pathway. Notably,
pretreatment with KA significantly attenuated liver injury induced
by HFPO-DA exposure in mice, highlighting the pivotal roles of KA
in the hepatotoxicity of HFPO-DA.